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Abstract
Background: Although the AIB1 oncogene has an important role during the early phase of the cell cycle as a coactivator of
E2F1, little is known about its function during mitosis.
Methodology/Principal Findings: Mitotic cells isolated by nocodazole treatment as well as by shake-off revealed a post-
translational modification occurring in AIB1 specifically during mitosis. This modification was sensitive to the treatment with
phosphatase, suggesting its modification by phosphorylation. Using specific inhibitors and in vitro kinase assays we
demonstrate that AIB1 is phosphorylated on Ser728 and Ser867 by Cdk1/cyclin B at the onset of mitosis and remains
phosphorylated until exit from M phase. Differences in the sensitivity to phosphatase inhibitors suggest that PP1 mediates
dephosphorylation of AIB1 at the end of mitosis. The phosphorylation of AIB1 during mitosis was not associated with
ubiquitylation or degradation, as confirmed by western blotting and flow cytometry analysis. In addition, luciferase reporter
assays showed that this phosphorylation did not alter the transcriptional properties of AIB1. Importantly, fluorescence
microscopy and sub-cellular fractionation showed that AIB1 phosphorylation correlated with the exclusion from the
condensed chromatin, thus preventing access to the promoters of AIB1-dependent genes. Phospho-specific antibodies
developed against Ser728 further demonstrated the presence of phosphorylated AIB1 only in mitotic cells where it was
localized preferentially in the periphery of the cell.
Conclusions: Collectively, our results describe a new mechanism for the regulation of AIB1 during mitosis, whereby
phosphorylation of AIB1 by Cdk1 correlates with the subcellular redistribution of AIB1 from a chromatin-associated state in
interphase to a more peripheral localization during mitosis. At the exit of mitosis, AIB1 is dephosphorylated, presumably by
PP1. This exclusion from chromatin during mitosis may represent a mechanism for governing the transcriptional activity of
AIB1.
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Introduction
The overexpression of AIB1, a transcriptional coactivator,
promotes pre-neoplastic changes and cancer initiation in animal
models [1,2]. The mechanisms by which AIB1 alter cell growth
involve a variety of signaling pathways including ER, IGF/PI3K/
AKT, HER2, NF-kB and Ets (reviewed in [3]. Interestingly,
overexpression of AIB1 is correlated with tumor invasiveness and
high levels of Twist [4]. AIB1 also functions as a coactivator of AP-
1 to up-regulate the expression of MMP-7 and MMP-10 in breast
cancer cell lines [5]. However, the expression level of AIB1 is not
the only determinant of its oncogenic potential since post-
translational modifications such as phosphorylation, ubiquityla-
tion, sumoylation, and acetylation (reviewed in [6] have been
demonstrated to modulate the activity of AIB1. Moreover, the
sub-cellular localization of AIB1 is an important parameter in the
regulation of this coactivator [7].
Most of the studies related to AIB1 and cell-cycle regulation
have focused on G1/S progression. During this phase, AIB1 is
localized, along with ERa, to the active promoter of cyclin D1 [8].
In addition, AIB1 promotes G1 progression by coactivating the
transcription of E2F1 [9]. Cyclin A and cyclin E are regulated
transcriptionally by the complex AIB1/E2F1 in the G1 to S
transition [10]. AIB1 also appears to have an important role
during or after S phase of the cell cycle [1,10]. However, very little
is known about the function of AIB1 during mitosis. One study has
shown that AIB1 is essential for the phosphorylation of histone H3
at serine 10 [11], a conserved molecular mechanism which is
accompanied by chromosome condensation in mitosis [12].
The events of mitosis, including reorganization of the cellular
architecture and chromosome condensation, require fine tuning to
ensure the precision of the cell-cycle. These processes are
coordinated by different families of kinases that trigger protein
phosphorylation cascades. The cyclin-dependent kinase Cdk1 is a
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late G2 initiates the cellular reorganization which also involves the
activity of three other kinase families: Aurora, Polo-like (Plk) and
NIMA-related (Nrk) kinases. Although both Aurora A and Plk1
are activated during early G2 [13], their activity as well as their
expression levels peak during M phase [14,15], as part of a
feedback loop with Cdk1. Aurora A and Plk1 are not required for
onset of mitosis, revealing a unique role of Cdk1 in G2/M
progression [16]. Activation of Plk1 by Aurora A facilitates mitotic
entry as well as checkpoint recovery [13,17]. In addition, Nrk
kinases participate in microtubule dynamics from late G2 through
mitosis [18].
With the present study, we demonstrate that AIB1 associates
with Cdk1 and undergoes phosphorylation just at the entry to
mitosis. This phosphorylation event is dependent on cyclin B but
not cyclin A, further supporting the phosphorylation of AIB1 at
the onset of mitosis. Interestingly, neither ubiquitylation nor
protein degradation were associated with this phosphorylation.
AIB1 remains phosphorylated throughout M phase and is
dephosphorylated only at the exit from mitosis, coinciding with
activation of PP1 and the inactivation of Cdk1. Importantly,
phosphorylation at the defined sites did not alter the transcrip-
tional activity of AIB1 but rather excludes this factor from
chromatin during mitosis, perhaps reflecting a mechanism to
prevent abnormal transcription during M phase. Collectively,
these results reveal a novel mechanism for regulating AIB1 during
mitosis by which chromatin exclusion and subcellular redistribu-
tion of AIB1 during mitosis may restrict its transcriptional activity.
Results
The electrophoretic mobility of AIB1 is reduced in mitosis
Regulation of AIB1 activity and stability is mediated by several
post-translational modifications. To study the cell cycle-dependent
post-translational modifications of AIB1, we analyzed synchro-
nized cultures of HeLa cells. These cells were arrested at different
stages of the cell cycle (see scheme above the western blots in
Figure 1A) and subsequently, analyzed by Western blotting. When
cells were arrested by nocodazole in prometaphase, AIB1 was
detected as a doublet (Figure 1A, lane 6). Similar results were
obtained from other tumor cell lines arrested with nocodazole
(data not shown), suggesting that this modification of AIB1 during
cell-cycle arrest is not specific to HeLa cells.
Nocodazole-treated cells round-up and detach from the culture
plates (Figure 1B), a morphology typical of mitosis. We used this
fact to separate fully mitotic cells (rounded up cells) from those that
had not yet entered mitosis (adherent cells). Interestingly, the only
band detected by anti-AIB1 antibodies in rounded up cells was the
upper band (slower mobility) of the doublet observed previously in
nocodazole-arrested cultures (Figure 1C). Consistent with this, the
Figure 1. Post-translational modification of AIB1 occurs at the entry to mitosis. (A) Western blot analysis of HeLa cells arrested at the
different stages of the cell-cycle as indicated in the scheme. Anti-AIB1 antibodies reveal an electrophoretic mobility shift in mitotic cells (lane 6).
Antibodies against indicated cyclins were used to confirm cell-cycle progression through the different stages. b-actin was used as loading control.
Chemically-induced cell cycle arrest was produced using the following drugs at the doses and times described in materials and methods: lane 1:
cyclosporin A; lane 2: wortmannin; lane 3: L-mimosine; lane 4: hydroxyurea; lane 5: etoposide, and lane 6: nocodazole. (B) Morphology of
asynchronous culture of HeLa cells and cells treated with nocodazole to arrest them at the beginning of mitosis. Rounded up cells (light refracting)
are cells that have entered mitosis. The increased number of rounded uping cells under nocodazole treatment visually confirms the enriched mitotic
population. (C) Western blot analysis of asynchronous growing cells (A), nocodazole-treated cells and mitotic cells (M) isolated from an asynchronous
culture by shake-off. Nocodazole-treated cells were divided into rounded up cells (R.up) and those that still remained attached (Adh.) to the surfaceo f
the culture dish. (D) Flow cytometry analysis was used to confirm the DNA content of cells treated as indicated in (C).
doi:10.1371/journal.pone.0028602.g001
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selected by shake-off from an asynchronous culture (a classical
method for isolating mitotic cells by mechanical agitation),
suggesting that it was not an artifact of the nocodazole treatment
(Figure 1C, lane M). In parallel, flow cytometry analysis confirmed
that the DNA content of nocodazole-treated and mitotic shake-off
cells was double that of control cells, as expected for cells at G2/M
(Figure 1D). These results demonstrate that AIB1 undergoes post-
translational modification at mitosis that significantly retards its
electrophoretic mobility.
AIB1 is phosphorylated during mitosis
We and others have shown previously that AIB1 is ubiquitilated
and degraded by the proteasome [7,19,20]. To identify the AIB1
modification which occurs at or during mitosis, we first assessed
ubiquitilation. The HeLa cell line constitutively expressing
6xhistidine-tagged ubiquitin constitutes a very appropriate biolog-
ical system for this study. Cells can be lysed under denaturing
conditions and ubiquitilated proteins bind to Ni
2+-column without
undergoing degradation or ubiquitylation during the process.
Ubiquitilated AIB1 was enriched in the Ni
2+-bound fraction of
asynchronous cells and displayed a slight retardation of electro-
phoretic mobility in contrast to the total extract (Figure 2A). The
ubiquitin-enriched fraction from mitotic cells revealed that AIB1
was also ubiquitilated (right M lane, Figure 2A). However,
ubiquitilated AIB1 at mitosis did not display the same mobility
as in whole cell extracts (compare both M lanes, Figure 2A). These
results suggest that AIB1 is weakly ubiquitilated during mitosis but
this does not produce the same band-shift as detected in whole cell
lysates. We then performed an in vitro assay with USP2, a potent
deubiquitilase. As expected, many proteins from the whole cell
extract were deubiquitilated after USP2 treatment; however, AIB1
from mitotic cells was only slightly, if at all, altered by USP2
(Figure 2B). To further evaluate whether AIB1 is ubiquitilated
during M phase, we used a third approach with antibodies that
detect both, mono- and poly-ubiquitilated proteins. However, the
results of the Western blots reveal that these antibodies did not
recognize AIB1 from mitotic cells (Figure 2C, compare upper and
lower panels). Collectively, these experiments exclude the
ubiquitilation pathway as a potential explanation for the retarded
electrophoretic mobility of AIB1 in cells at M phase.
We then explored whether the altered mobility of AIB1 detected
in mitotic cells is the result of phosphorylation. Thus, lysates from
cells arrested at mitosis were subjected to various protein
phosphatases. Treatment with l protein phosphatase, but not
alkaline phosphatase, restored the AIB1 doublet to the faster
migrating single band observed in asynchronized cultures
(Figure 3A), suggesting that alterations of mobility observed in
mitotic cells were due mostly to phosphorylation. To test whether
Cdk1 might participate in the phosphorylation of AIB1 at M
phase, we used the Cdk inhibitor purvalanol A. Cells arrested at
mitosis with nocodazole and further treated with purvalanol A did
Figure 2. Post-translational modification of AIB1 at mitosis does not correlate with ubiquitination. (A) HeLa cells constitutively
expressing 6xhistidine tagged-ubiquitin were grown asynchronously or arrested at mitosis with nocodazole and cell lysates were either directly
analyzed (total extract) or subjected to purification through a Ni
2+-agarose column and further analyzed by western blotting. Arrow indicates the
AIB1 mitotic-specific band. (B) MCF-7 cell extracts (30 mg, 1:100) from arrested cells with nocodazole were subjected to enzymatic assay with the
300 ng of deubiquitinating enzyme GST-USP2 in 50 ml deubiquitylation buffer (50 mM Tris-HCl pH 7.5, 1 mM EDTA, 1 mM DTT). Samples were
analyzed by western blot with anti-mono, poly-ubiquitin antibodies and anti-AIB1 antibodies. The altered electrophoretic mobility of the AIB1 bandi s
indicated with an arrow, demonstrating insensitivity to USP2 activity. (C) HeLa cells were grown asynchronously, or treated with the proteasome
inhibitor MG132, or with etoposide to arrest them at G2 or with nocodazole to arrest them at mitosis (M). Cell lysates were immunoprecipitated with
AIB1 antibodies and immunocomplexes were analyzed by western blotting with anti-mono, poly-ubiquitin antibodies and anti-AIB1 antibodies. The
arrow indicates the mitosis-specific AIB1 band that is not detected with ubiquitin antibodies.
doi:10.1371/journal.pone.0028602.g002
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(Figure 3B). Although highly specific for Cdk, purvalanol A has
also been reported to weakly inhibit ERKs. Given that AIB1 can
be phosphorylated by ERKs [21], nocodazole-arrested cells were
subsequently treated with the MEK inhibitor PD98059 to
specifically block the phosphorylation and activation of ERKs
during mitosis. Although PD98059 inhibited ERKs phosphoryla-
tion, the electrophoretic mobility of AIB1 was not altered by this
treatment (Figure 3C). Similarly, treatment of mitotic cells with
specific inhibitors of Aurora A/B, Plk1-4 or Nek2 did not cause
dephosphorylation of AIB1 (Figure 4). Thus, these results suggest
that the phosphorylation of AIB1 at mitosis is Cdk1-dependent.
To further test this hypothesis, we expressed full-length AIB1 in
Sf9 cells and the purified protein was subjected to an in vitro kinase
assay with active Cdk1/cyclin B1. AIB1 was detected as a radio-
labeled protein (Figure 3E), demonstrating that it is a direct
substrate of Cdk1/cyclin B1 in vitro. Consistent with this,
immunoprecipitation of AIB1 from asynchronous (A) or mitotic
(M) culture lysates revealed the presence of Cdk1 in AIB1
immunocomplexes, suggesting a functional relationship in vivo
between these proteins (Figure 3D).
AIB1 is dephosphorylated at the exit from mitosis
One consequence of the exit from mitosis is the dephosphor-
ylation of multiple structural and regulatory proteins; the protein
phosphatase 1 (PP1) is responsible for the majority of this
dephosphorylation activity [22]. Cdk1 phosphorylates PP1 at
threonine 320 and inhibits its activity [23]. To assess the
phosphorylation status of AIB1 at the end of M phase, rounded
up HeLa cells arrested at mitosis with nocodazole were isolated,
washed and allowed to proceed through mitosis in normal growth
medium. The majority of AIB1 was dephosphorylated 5 hours
after release from the nocodazole blockade, coinciding with the
degradation of cyclin B1 and the dephosphorylation (and
therefore the reactivation) of PP1 (Figure 5A, left panels). In
parallel, flow cytometry analysis confirmed that although some
cells were reentering G1 after 3 hours, at 5 hours most of them
had exited mitosis and were already at G1 (Figure 5B, upper
graphs). In addition, treatment with the proteasome inhibitor
MG132 arrested cells at mitosis (Figure 5B, lower graph).
Western blot analysis of these lysates revealed that MG132
blocked cyclin B1 degradation, PP1 reactivation and the de-
phosporylation of AIB1 at exit of mitosis (Figure 5A, right lanes in
Figure 3. AIB1 is phosphorylated at entry to M phase by Cdk1/cyclin B. (A) Western blot analysis of 30 mg of cleared lysates from
nocodazole-arrested HeLa cell which were treated with the indicated phosphatases for 1.5 h at 30uC. Phospho-Akt antibodies were used as a control
of the enzymatic activity. (B) Cells arrested at mitosis with nocodazole were further treated with vehicle alone (2) or with the Cdk1 inhibitor
purvalanol A 10 mM (+) during 3 hours. Anti-lamin A/C antibodies were used to control loading. (C) Mitotic cells were treated with the MEK inhibitor
PD98059 20 mM( +) or with vehicle alone (2) and cell lysates were analyzed by western blotting with AIB1 antibodies. Phospho-ERK specific
antibodies were used as control for the efficiency of the treatment. (D) Western blot analysis of immunoprecipitated complexes using anti-AIB1
antibodies or pre-immune serum (Pre-I) from lysates of asynchronous HeLa cells (A) or from cells arrested with nocodazole (M). (E) Human AIB1 was
subcloned in pFASTBac HTa and baculovirus were produced to express the recombinant full-length His6-AIB1 in Sf9 cells using the system BacPak
(Clontech). Recombinant protein was purified by standard Ni
2+-NTA affinity chromatography followed by desalting with a molecular exclusion
column. Purified AIB1 (middle panel) was incubated with [c-
32P]ATP in the presence (+) or absence (2) of recombinant Cdk1/cyclin B1 for 1 hour at
30uC (upper panel). Reactions were resolved by SDS-PAGE, the gel was dryed and exposed to an X-ray film. 1 mg of histone H1 (Sigma) was used as a
positive control (bottom panel).
doi:10.1371/journal.pone.0028602.g003
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AIB1 at the termination of M phase coincides with the re-
activation of PP1.
To further substantiate the dephosphorylation of AIB1 at the
exit from mitosis, rounded up cells were separated from adherent
cells 3 hours after their release from nocodazole-mediated arrest
and were analyzed by western blotting. Interestingly, AIB1 was
completely dephosphorylated in adherent cells that represent G1,
whereas the rounded up fraction of cells retained at M contained
only phosphorylated AIB1 as evidenced by the slower mobility of
this band (Figure 5C).
To investigate the turnover of AIB1 during mitosis rounded up
HeLa cells were collected after nocodazole treatment and allowed
to recover in the presence of cycloheximide to block de novo protein
synthesis. Based on flow cytometry analysis, cells treated with
cycloheximide were able to complete mitosis, although no cyclin
D1 was synthesized (Figure 5D). Under these conditions, the AIB1
band shift was barely detectable after 5 hours (Figure 5A, right
panels). Furthermore, treatment with the proteasome inhibitor
MG132 did not promote the accumulation of AIB1. These results
demonstrate that phosphorylated AIB1 is not degraded by the
proteasome and strengthen the argument that it is dephosphor-
ylated at exit from M phase. Similar results were obtained with
MCF-7 cells, although the dephosphorylation of AIB1 occured
earlier in this cell line (Figure 6).
AIB1 phosphatase is partially resistant to okadaic acid but
inhibited by calyculin A
Okadaic acid is a specific inhibitor for phosphatases PP1 and
PP2A. However, PP2A is much more sensitive to okadaic acid
than PP1. To distinguish between the activities of these
phosphatases, cell cultures were synchronized at mitosis and
then were allowed to complete mitosis in the presence or absence
of okadaic acid. The concentration was adjusted to inhibit PP2A
alone (0.1 mM) or both PP1 and PP2A (0.5 mM). Okadaic acid
blocked the dephosphorylation of AIB1 in HeLa cells in a dose-
dependent manner (Figure 7A, left panels), suggesting that
indeed PP1 dephosphorylates AIB1 at the exit of mitosis. In
MCF7 cells, okadaic acid has been reported to more potently
inhibit PP2A than PP1 [24]. Consistent with this, treatment with
okadaic acid was much less efficient at blocking dephosphory-
lation of AIB1 in MCF-7 cells than in HeLa cells (Figure 7A,
compare left and right panels). The PP2B specific inhibitor
cyclosporine A had no effect on the dephosphorylation of AIB1
in HeLa cells (Figure 7B).
Calyculin A is a more effective inhibitor of both PP1 and
PP2A than okadaic acid. Hence, we then compared these
inhibitors in nocodazole-arrested HeLa cells. The dephosphor-
ylation of AIB1 was only partially inhibited in the presence of
okadaic acid (Figure 7C, third lane) whereas calyculin A
completely blocked AIB1 dephosphorylation. One plausible
interpretation of these results is that inhibition of the phospha-
tase prevents the inactivation of Cdk1, thereby maintaining
AIB1 in a phosphorylated state. To evaluate this hypothesis, we
further tested phosphatase inhibitors in the presence of
purvalanol A. Similar to the results of Figure 4, treatment of
nocodazole-arrested cells with the Cdk inhibitor purvalanol A
promoted the dephosphorylation of AIB1 and the reactivation
(absence of phosphorylation at threonine 320) of PP1 (Figure 7D).
Treatment with 0.2 mM okadaic acid in the presence of
purvalanol A did not prevent AIB1 dephosphorylation and
PP1 reactivation. However, treatment with calyculin A blocked
completely the dephosphorylation of AIB1 and increased PP1
phosphorylation/inactivation (Figure 7D). Collectively, these
results demonstrate that AIB1 is dephosphorylated at the exit
from mitosis, most likely by PP1.
Cyclin B but not cyclin A participates in the Cdk-
mediated phosphorylation of AIB1
To identify the site(s) targeted by Cdk1, we generated various
AIB1 fragments (named A through E) that span the full-length
sequence (Figure 8A). Fragments were expressed in bacteria
(Figure 8D) and subjected to in vitro kinase assays with
complexes of cyclin B1/Cdk1 (Figure 8B) or cyclin A2/Cdk1
(Figure 8C). Fragment C was highly phosphorylated by cyclin
B1/Cdk1 but not by cyclinA/Cdk1. The amino-terminal
fragment A was weakly phosphorylated by this complex but
none of the other AIB1 fragments were radiolabeled upon
incubation with cyclin A1/Cdk1 (Figure 8C), further supporting
the notion that AIB1 is phosphorylated by Cdk1 just at the
entry of M phase.
Interestingly, Fragment C contains a perfect consensus sequence
for Cdk phosphorylation at S728. Additionally, eleven amino acids
ahead of S728 is a cyclin binding motif (RXL), constituting a
bipartite recognition motif for cyclin-dependent kinases [25]. To
test whether the S728 serves as a substrate for cyclin B1/Cdk1, this
site was mutated to alanine. The phosphorylation of the mutated
Fragment C by Cdk1 was significantly reduced compared to the
wild-type fragment (Figure 8E, compare C vs. C S728A). We also
Figure 4. AIB1 is not a substrate of Aurora A, B, Plks or Nek2.
Floating HeLa cells arrested at mitosis with nocodazole were further
treated for three more hours with vehicle alone as control (lane 1),
10 mM purvalanol A (lane 2), 1.25 mM Aurora kinase inhibitor II (lane 3),
7 mM Plk inhibitor III (lane 4) or 100 mM of the Hec1/Nek2 inhibitor I
(lane 5). Cells were lysed and analyzed by westernblotting against the
indicated molecular species. Importantly, exposure of cells to the Cdk1
inhibitor caused the desphosphorylation of AIB1 together with a rapid
mitotic exit (lane 2) to a similar extent as previously reported with other
inhibitors [31,32]. On the other hand, exposure of mitotic cells to
inhibitors specific for Aurora A, B, Plks or Nek2 did not show any
significant effect on AIB1 phosphorylation, suggesting that neither of
them is a kinase for AIB1 under the experimental conditions tested. The
protein kinase inhibitor staurosporine causes morphological changes at
mitosis in HeLa cells, including the decondensation of chromosomes
and the reformation of nuclear membrane [33]. Treatment with the
different kinase inhibitors at the concentrations indicated by the
supplier caused similar morphological changes plus the reattachment
of cells to the surface of the petri dish (data not shown), suggesting that
the inhibitors indeed exerted a biologically relevant activity.
doi:10.1371/journal.pone.0028602.g004
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washed with PBS and allowed to progress through mitosis for the times indicated, in the presence or absence of 20 mM MG132 and 10 mg/ml
cycloheximide (CHX). Western blot analysis was performed for AIB1 to monitor its phosphorylation status. b-actin were assessed as loading control.
(B) Flow cytometry analysis of HeLa cells treated as above. (C) HeLa cells arrested at mitosis were allowed to progress through cell cycle and at
3 hours, the remaining rounded up cells (R.up) were separated from adherent cells (Adh.) and analyzed by western blotting. (D) Rounded up HeLa
cells recovered after nocodazole treatment were washed with PBS and allowed to progress through mitosis for the indicated times in the absence or
presence of 10 mg/ml cycloheximide (CHX).
doi:10.1371/journal.pone.0028602.g005
Figure 6. Desphosphorylation of AIB1 occurs at mitosis exit. (A) Floating MCF7 cells arrested at mitosis with nocodazole were washed and
liberated to progress through mitosis for the times indicated, in the presence or absence of 20 mM MG132 and 10 mg/ml cycloheximide (CHX).
Western blot analysis was performed for AIB1 to monitor its phosphorylation status. Cyclin B1, protein phosphatase 1 (PP1), and the inhibitory
phosphorylation of PP1 (P-PP1) were also assessed. b-actin was used as a loading control. (B) Flow cytometry analysis of MCF-7 cells treated as above
was used to confirm cell-cycle progression as determined by DNA content.
doi:10.1371/journal.pone.0028602.g006
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with S728A completely abolished the Cdk1-mediated phosphor-
ylation (Figure 8E, right lane). Moreover, mutation of RYL cyclin
binding domain to AYA reduced by 50% the incorporation of
radioactivity (Figure 8F), suggesting that it is required for complete
phosphorylation of AIB1 by Cdk1. Our data support the notion
that serine 728 is the major site for in vitro phosphorylation of
AIB1, although we cannot exclude other sites that were not
detected due such factors as the mis-folding of the recombinant
protein fragments.
Phosphorylated AIB1 is excluded from mitotic chromatin
We next investigated whether the phosphorylation state of AIB1
might modulate its sub-cellular localization. Proliferating MCF-7
cells were stained with anti-AIB1 antibodies and mitotic cells were
identified by DAPI or anti-tubulin staining. Our results reveal that
AIB1 is excluded from chromatin in mitotic cells (Figure 9, A and
B), suggesting that phosphorylation of this molecule may regulate
its access to chromatin. To investigate the relation between Cdk1-
mediated phosphorylation of AIB1 and its exclusion from
chromatin, cells that adhered after nocodazole-treatment were
lysed to obtain soluble (cytosol and nucleoplasm) and insoluble
(enriched with proteins bound to chromatin and nuclear matrix)
fractions [26]. Adherent cells contain phosphorylated and unpho-
sphorylated AIB1 (Figure 1C, second lane) and thus, constitute the
adequate cellular population to study differences between both
AIB1 species. Interestingly, the mobility of AIB1 was retarded only
in the soluble fraction (Figure 9C), whereas the band representing
dephosphorylated AIB1 band was enriched in the insoluble
fraction (Figure 9C, compare S and I lanes). These findings
further support our observation that phosphorylation of AIB1
facilitates its exclusion from chromatin. We also generated
phospho-specific antibodies directed against phosphorylated
AIB1 at Ser728. These antibodies stained exclusively mitotic cells
where AIB1 was localized to the periphery of the cell, suggesting
its exclusion from chromatin during mitosis (Figure 10A). These
results further suggest a correlation between the phosphorylation
of AIB1 at Ser728 and its sub-cellular redistribution during
mitosis. Consistent with this, western blot analysis with these
phospho-specific antibodies detected only the retarded electro-
phoretic mobility band characteristic of AIB1 during mitosis
(Figure 10B).
To assess the effects of phosphorylation on the transcriptional
activity of AIB1, we fused full-length AIB1 to the DNA binding
domain of Gal4 (Gal4-DBD) and co-transfected it with the
luciferase reporter driven by the Gal4 responsive element. COS1
cells were treated with nocodazole prior to analysis. No significant
differences were detected between AIB1 with the mutation at S728
and wild-type AIB1 (Figure 11A). Alternatively, phosphorylation
could alter the capacity of AIB1 to bind other transcriptional
factors without affecting its capacity to activate the transcriptional
machinery. To test this alternate hypothesis, we used an estrogen
receptor alpha (ERa)-dependent co-activation assay. Neither of
the AIB1 mutants (S728A or S728E) displayed notable differences
of coactivation capacity when compared to wild-type AIB1. These
results suggest that the phosphorylation of AIB1 during mitosis
does not modulate its transcriptional capacity and ability to
coactivate ERa.
Figure 7. The dephosphorylation of AIB1 at the exit from mitosis is sensitive to okadaic acid and caliculin A inhibitors. (A) Mitotic
HeLa and MCF-7 cells were allowed to progress through mitosis for the indicated times, in the presence or absence of the indicated concentrations of
okadaic acid (OA). Cell lysates were analyzed subsequently by western blotting with AIB1 antibodies to detect the mitotic specific band and b-actin as
loading control. (B) Western blot analysis of mitotic HeLa cells allowed to progress through mitosis for the indicated times, in the presence or absence
of 5 mM cyclosporin A. (C) Rounded up HeLa cells arrested in mitosis as in (A) were allowed to progress through cell cycle in the absence (2)o r
presence (+) of 0.2 mM okadaic acid (OA) or 20 nM caliculin A for 5 hours. Cell lysates were analyzed by western blotting as indicated. (D) Western
blot analysis of AIB1 phosphorylation status and other indicated molecular species from nocodazole-arrested HeLa cells further treated (+) with
10 mM purvalanol A, 0.2 mM okadaic acid (OA) or 20 nM caliculin A.
doi:10.1371/journal.pone.0028602.g007
AIB1 Is Excluded from the Chromatin during Mitosis
PLoS ONE | www.plosone.org 7 December 2011 | Volume 6 | Issue 12 | e28602Discussion
Phosphorylation of proteins during mitosis and their dephos-
phorylation at the exit from mitosis require precise regulation to
maintain the integrity of the cell-cycle. The function of the
transcriptional coactivator AIB1 has been studied extensively in
the progression of G1 to S but little is known about its role in M
phase. AIB1 is the target of various kinases that regulate both its
function and its turnover. Our results demonstrate that AIB1 also
serves as a substrate of Cdk1/cyclin B just at the entrance of
mitosis, thus providing a new mechanism for regulating AIB1
during the cell cycle. We found that phosphorylation of AIB1
occurs solely in mitotic cells and that this molecule remains
phosphorylated throughout mitosis. Consistent with this, Cdk1
associated with cyclin B not cyclin A was able to phosphorylate
AIB1 in vitro, suggesting that this phosphorylation event does not
occur at G2 but rather exclusively at M phase, when the cyclin B/
Cdk1 complex is active in dividing cells.
Mitogenic stimuli that promote cell-cycle progression through
G1/S trigger the activation of signaling kinases such as ERKs and
AKT. Phosphorylation of AIB1 by ERKs at multiple residues
results in the recruitment of p300 and enhances its coactivation
capacity [21]. On the other hand, PI3K/AKT can stabilize AIB1
and prevent its degradation by the proteasome [7]. GSK3 can also
phosphorylate AIB1 at S505, coupling AIB1 to mono-ubiquityla-
tion and further poly-ubiquitylation at K723 and K786, resulting
in its recognition by the proteasome [20]. Ubiquitylation at K1194
has also been detected, but it does not induce proteasomal
degradation, although it is required for a full coactivation by the
proteasome [7]. Thus, activation of the ERK and PI3K/AKT
pathways enhance AIB1 activity and stability. To investigate
whether the phosphorylation of AIB1 during M is also associated
with ubiquitylation, we used three different experimental strategies
(Figure 2). However, we were unable to demonstrate that mitotic
AIB1 is ubiquitilated, suggesting that phosphorylation of AIB1
during mitosis does not result in ubiquitin-proteasome degradation
or ubiquitin-dependent trafficking. Moreover, AIB1 protein levels
remain constant throughout mitosis (Figure 5), providing addi-
tional evidence that the phosphorylation at the onset of M is not
associated with degradation but may rather regulate the activity of
AIB1. Treatment of phosphorylated AIB1 with protein phospha-
tase alone completed restored the doublet to a single band,
suggesting that phosphorylation was the only post-translational
modification that occurs to AIB1 at mitosis. A previous study has
shown that sumoylation coordinated with phosphorylation regu-
lates the transcriptional activity of AIB1 [27]. However, our
Figure 8. AIB1 is phosphorylated by Cdk1/cyclin B but not Cdk1/Cyclin A. (A) Representative scheme of full length AIB1 and GST fusion
fragments generated and named A through E. (B) Qualitative analysis of AIB1 fragments subjected to in vitro phosphorylation with active Cdk1/cyclin
B. Reactions were resolved by SDS-PAGE and gel, dried on Whatman paper and exposed for autoradiography. Fragment containing amino acids 792–
928 of the Retinoblastoma protein (Rb) was also expressed as a GST fussion protein and 1 mg was used in a parallel reaction as a positive control. (C)
Same fragments as in (B) were also incubated with 100 ng of active Cdk1/Cyclin A2 (Cell Signaling). (D) Coomassie staining of the different AIB1
fragments fused to GST. Based in the cualitative amounts of proteins stained, double input of fragment E was used in the radioactive reactions. (E)
Autoradiography (upper panel) of AIB1 fragment C (aminoacids 693–933) and fragments harbouring point substitutions serine 728 to alanine
(S728A), serine 860 to alanine (S860A) and serine 867 to alanine (S867A), subjected to phosphorylation by complex Cdk1/cyclin B1 in the presence of
[c-
32P]ATP, 1 hour at 30uC. Bottom panel represents a Coomassie staining of the fragments used in the upper kinase reactions. (F) Autoradiography
exposure (upper panel) and coomassie staining (lower panel) of AIB1 fragment C and a mutant (C AYA) in which amino acids RYL localized at +11
from serine 728 are mutated to AYA. Fragments were incubated with active Cdk1/cyclin B1 for 1 hour at 30uC in the presence of [c-
32P]ATP. Reactions
were resolved by SDS-PAGE and gel, dried on Whatman paper and exposed for autoradiography. Fragment containing amino acids 792–928 of the
Retinoblastoma protein (Rb) was also expressed as a GST fusion protein and used in a parallel reaction as a positive control.
doi:10.1371/journal.pone.0028602.g008
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with specific antibodies produced negative results (data not
shown).
We have identified two serines (728 and 867) which were
phosphorylated by Cdk1 in an in vitro kinase assay. Ser728 is
potently phosphorylated by Cdk1 and is within the motif (S/
T)PX(R/K) (where X is any amino acid) found in most Cdk
substrates. Both sites have recently been reported to be
phosphorylated using a high throughput proteomics analysis
[28]. However, the data in this study suggest that they are
predominantly phosphorylated at G1. In contrast, our results
demonstrate that phosphorylation at those sites occurs only by
Cdk1/cyclinB. In addition, we show that AIB1 is dephosphory-
lated at the exit from mitosis. Hence, our data suggest strongly that
phosphorylation occurs at these sites during mitosis but not during
G1. Sequence analysis revealed a cyclin binding motif localized 11
aminoacids downstream of S728. Mutation of this motif reduced
but did not attenuate completely the phosphorylation at S728 by
the cyclinB/cdk1 complex. These results suggest that the cyclin
binding motif is relevant but not essential for AIB1 phosphory-
lation by Cdk1.
During interphase, transcription factors and related proteins are
frequently redistributed within the nucleus of cells. Many of these
proteins (such as RNA polymerase II) are displaced from
chromatin during mitosis, whereas others like TFIID and TFIIB
can remain associated with active gene promoters during mitosis
[29]. Immunofluorescence staining revealed that in mitotic cells
AIB1 is excluded completely from the condensed chromatin.
Interestingly, phosphorylation of the transcriptional coactivator
BRG1 during mitosis correlates with decreased affinity for nuclear
structure but does not disrupt the association with SNF5 [26].
Similarly, we found that phosphorylated AIB1 associated with
mitosis is exclusively detected in the soluble fraction that lacks
chromatin-bound proteins. In our experiments to test whether
phosphorylation of AIB1 during mitosis modulates its transcrip-
tional activity, we used transient transfection of plasmids harboring
the luciferase reporter gene under the control of either Gal4-DBD
or ER responsive elements. These results demonstrate that, in
contrast to its exclusion from native chromatin during M phase of
dividing cells, AIB1 and other factors of the basal transcriptional
machinery are recruited to the luciferase promoter to transcribe
the luciferase gene during mitosis. One plausible explanation for
these results is that these plasmids and their minimal promoters
are not subjected to the same epigenetic complexities as
endogenous promoters of the chromatin. Point mutations at
Ser728 of AIB1 did not alter the endogenous transcriptional
activity or the capacity to coactivate ERa. These results reveal that
phosphorylation of AIB1 on S728 by Cdk1 does not regulate its
activity or association with transcription factors. However, it
remains possible that phosphorylation at additional sites would
induce changes in the transcriptional capacity of AIB1. Never-
theless, phosphorylation by Cdk1 promotes exclusion from the
chromatin and therefore, physically restricts AIB1-dependent
transcriptional activation during mitosis. Based on this model,
dephosphorylation of AIB1 at exit from M would restore its
capacity to coactivate the transcription of genes implicated in
Figure 9. The band-shifted AIB1 is associated with the soluble fraction of cell lysates and is excluded from mitotic chromatin. (A)
Asynchonous culture of MCF-7 cells were used for an immunofluorescence assay with anti-AIB1 antibodies (red) and DAPI (blue) to stain the
chromatin. Bottom panels represent merged images. Scale bar: 10 mm. Mitotic cells are indicated with an arrow demonstrate that AIB1 is excluded
from chromatin. (B) Confocal microscopy analysis of same cells as in (A) stained with anti-AIB1 (Alexa Fluor 488) and anti-b-tubulin (Alexa Fluor 633) to
reveal the mitotic spindle. (C) MCF-7 and HeLa cells were arrested at mitosis with nocodazole and adherent cells were further subjected to cellular
fractionation based on the treatment with two subsequent lysis buffers. The first buffer with low ionic strength completely solubilized the
phosphorylated AIB1 (upper band, lane S). The second buffer containing high ionic strength extracted only the lower AIB1 band (lane I), together
with the nuclear proteins lamin A/C, revealing non cross-contamination with the soluble fraction S.
doi:10.1371/journal.pone.0028602.g009
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dephosphorylate AIB1 at residues S101 and S102 [30], thus
preventing its ubiquitylation and degradation. However, our
findings demonstrate that dephosphorylation of AIB1 by PP1 at
the exit from mitosis does not influence protein stability but rather
facilitates subsequent re-entry of the cell cycle. Thus, dephosphor-
ylation of AIB1 may represent a novel biological target for
therapeutic interventions aimed at improving the outcome of
current treatments of AIB1-dependent cancers.
Materials and Methods
Cell culture, cell transfection and cell-cycle
synchronization
HeLa, MCF-7 and COS-1 cells (ATCC) were maintained in
DMEM–10%FBS(Invitrogen).Sf9cells(Invitrogen)werecultured
in SF-900 II medium (Invitrogen). Transfections in COS-1 cells
were performed with FuGene 6 (Roche) according to manufacturer
instructions. For synchronization, cells were deprived of serum for
Figure 10. Phospho-specific antibodies (pAIB1) confirm that AIB1 is phosphorylated on Ser728 exclusively during mitosis. (A)
Confocal microscopy analysis of an asynchonous culture of MCF-7 cells stained with DAPI (blue), anti-pAIB1(S728) (Alexa Fluor 488) and anti-b-tubulin
(Alexa Fluor 633) to reveal the mitotic spindle. Scale bar: 10 mm. Only mitotic cells stain positively with pAIB1(S728) antibodies and suggest that
pAIB1(S728) is excluded from chromatin. (B) Western blot analysis of MCF-7 cells arrested at mitosis with nocodazole. Cell lysates were probed with
the indicated antibodies, revealing that anti-pAIB1(S728) antibodies detect exclusively the slower electrophoretic mobility band.
doi:10.1371/journal.pone.0028602.g010
Figure 11. AIB1 phosphorylation at Serine 728 regulates its coactivation capacity. (A) To measure AIB1-dependent transcriptional activity,
COS-1 cells were transfected with 500 ng of reporter gene (56UAS-luciferase), 20 ng of tk-lacZ and 25 ng of empty vector pCMX-Gal4-DBD (control,
C) or 46.5 ng of pCMX-Gal4-DBD-AIB1 wild type or mutant. 30 hours after the transfection cells were arrested at mitosis with nocodazole (150 ng/ml)
for 17 hours. Finally, cells were lysed with passive lysis buffer (Promega) and tested for luciferase activity and normalized against b-gal activities in a
luminometer (Berthold Detection Systems). Results are presented as relative units to the control cells as mean values 6 S.E. (B) To measure AIB1-
dependent coactivation, COS-1 cells were transfected with the luciferase reporter ERE2-tk-luciferasa and vectors expressing ERa, AIB1 or the mutated
AIB1 (S728A) or (S728E). Cells were arrested at mitosis similarly to (A) and treated with 50 nM 17-b-estraxdiol during the last 5 hours.
doi:10.1371/journal.pone.0028602.g011
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16 h, 5 mM cyclosporin to arrest at G0/G1; 24 h with 100 nM
wortmannin for late G1, 24 h with 400 mM mimosine for G1/S,
48 h with 5 mM hydroxyurea for S-phase, 24 h with 10 mM
etoposide for G2/M and for 17 h with 150 ng/ml nocodazole for
M-phase (prometaphase) followed by shake-off to collect mitotic
cells. All inhibitors were purchased from Sigma. Mitotic cells were
washed and released for the indicated times in the presence or
absence of 10 mg/ml cycloheximide (Sigma), 20 mM MG132
(Calbiochem), 0.1–1 mM okadaic acid (Calbiochem) and 20 nM
calyculin A (Calbiochem). Alternatively, mitotic cells were resus-
pended in nocodazole containing media supplemented with 20 mM
PD98059 (Sigma) or 10 mM purvalanol A (Calbiochem) alone and/
or okadaic acid or calyculin A for 2 h.
Flow cytometry analysis
Cells were harvested by trypsin treatment, washed with PBS
and resuspended in 70% ethanol to permit fixation and
permeabilization at 220uC. Propidium iodide-stained cells
(5 mg/ml; Sigma) were analyzed using a flow cytometer (Cytomics
FC500; Beckam Coulter).
Protein extraction and Western blotting
Cells were washed with ice-cold PBS and lysed with commercial
lysis buffer (Cell Signaling) supplemented with protease cocktail
inhibitors (Roche), 1 mmol/l NaF and up to 300 mM NaCl. His6-
tagged proteins were lysed with 6 M guanidium-HCl, 0.1 M
Na2HPO4/NaH2PO4 and 0.1 M Tris-HCl pH 8, sonicated for
30 s and centrifuged for 15 min at 160006g. Cleared supernatant
was diluted 1:1 in PBS, and His6-tagged proteins were purified by
Ni
2+-NTA affinity chromatography (Qiagen) in the presence of
10 mM Imidazole (Merck), 1 mM AEBSF (Roche), 20 mM
MG132, 10 mM N-etilmaleimide (Sigma) and 5 nM ubiquitin
aldehyde (Santa Cruz Biotech) during 2 h at room temperature.
Agarose beads were then washed once with buffer A (same as lysis
buffer but with 10 mM imidazol), once with buffer B (8 M urea,
0.1 M Na2HPO4/NaH2PO4, 0.01 M Tris-HCl pH 8 and 10 mM
imidazol), four times with decreasing concentrations of Triton X-
100 (starting at 0.2%) in buffer C (8 M urea, 0.1 M Na2HPO4/
NaH2PO4, 0.01 M Tris-HCl pH 6.3 and 10 mM imidazol).
Finally, ubiquitylated proteins were eluted by boiling in Laemmli
buffer.
Subcellular fractionation was done as previously reported [26]
with the following adaptation: the insoluble pellet was extrated
with lysis buffer.
Samples were resolved in 7.5% or 15% SDS-PAGE, blotted to
Immobilon-P membranes (Millipore) and probed with the
following antibodies: monoclonal anti-AIB1 (BD Biosciences),
polyclonal anti-phospho-AKT Ser473, polyclonal anti-phospho-
Cdc2 Tyr15, polyclonal anti-phospho-PP1 Thr320 and polyclonal
anti-Cdc2 (Cell Signaling); monoclonal anti-phospho-ERK1/2
Tyr204, polyclonal anti-cyclin A, polyclonal anti-cyclin B1,
monoclonal anti-cyclin D1, polyclonal anti-cyclin E, polyclonal
anti-PP1, monoclonal anti-Lamin A/C from (Santa Cruz Biotech);
monoclonal anti-phospho-histone H3 from Millipore; monoclonal
anti-b-actin from Sigma and monoclonal anti-ubiquitin FK2
(Affinity Bioreagents). Phospho-specific anti-pAIB1(S728) were
raised in rabbits against the peptide KQEQL(pS)PKKKENNA.
Sera from the immunized rabbits were cleared with the unpho-
sphorylated peptide.
Immunoprecipitation
Pre-cleared whole-cell lysates (1 mg) were immunoprecipitated
with polyclonal AIB1 antibodies (generated in our laboratory)
during 4 h at 4uC. Protein A-agarose was added to immunocom-
plexes and incubated for 2 more hours. Immunocomplexes were
washed three times with lysis buffer and solubilized by boiling in
Laemmli buffer. Half of the immunoprecipitation was analyzed by
western blot. Preimmune serum was used as negative control.
DNA constructs and site directed mutagenesis
Plasmid constructs pGEX4T-1-AIB1(1–555), pGEX4T-3-
AIB1(693–933), pGEX4T-3-AIB1(934–1031) and pGEX4T-1-
AIB1(1032–1424) were generated by subcloning cleaved fragments
from pcDNA3.1+AIB1 with SspI and EcoRI. Construct
pGEX4T-1-AIB1(556–693) was generated by PCR to add
EcoRI-SalI sites. Point mutations S728A, S728E, S860A, S867A
and R739A/L741A were generated using QuickChange site-
directed mutagenesis kit (Stratagene). Mutations were verified by
sequencing.
Kinase assay- Recombinant full-length AIB1 protein produced in
Sf9 cells (1 mg) or GST-AIB1 fragments attached to the sepharose
beads (15 ml) were subjected to in vitro phosphorylation in a final
volumen of 30 ml with kinase buffer, 10 units of Cdk1-cyclin B1
complex (Cell Signaling), 200 mM ATP and 5 mCi [c-
32P]-ATP
(Perkin Elmer). Reactions were incubated for 1 h at 30uC,
analyzed by SDS-PAGE and exposed for autoradiography. 1 mg
of Histone H1 (Sigma) and 1 mg of GST-Retinoblastoma
(aminoacids 792–928) were used as positive controls. In vitro
phosphorylation by Cdk1-cyclin A2 complex (Cell Signaling) was
performed similarly as above, except that 100 ng of Cdk1-cyclin
A2 complex were used per reaction.
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